Evaluating the impact of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a study protocol for a randomized controlled trial

• Published in: BMC neurology Vol. 23; no. 1; p. 53
• Main Authors: Chu, Nathan Y, Watson, Kaitlyn E, Al Hamarneh, Yazid N, Yushko, Lily, Tsuyuki, Ross T, Smyth, Penelope
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.02.2023; BioMed Central; BMC
• Subjects: Anxiety; Anxiety - therapy; Anxiety Disorders; Care and treatment; Chronic illnesses; Clinical outcomes; Clinical trials; Depression; Depression - epidemiology; Depression - etiology; Depression - therapy; Depression, Mental; Diagnosis; Disease; Evaluation; Feasibility studies; HADS; Health care; Hospitals; Humans; Informed consent; Intervention; Mental depression; Mental disorders; Mental health; Methods; Multiple sclerosis; Multiple Sclerosis - complications; Multiple Sclerosis - psychology; Nurse practitioners; Outcome and process assessment (Health Care); Patient Reported Outcome Measures; Patient satisfaction; Patients; Psychological aspects; Quality of life; Questionnaires; Randomized Controlled Trials as Topic; Registration; Research ethics; Study Protocol; Alberta; Alberta Canada; Edmonton Alberta Canada; Canada; Healthcare delivery; Multiple sclerosis; Patient-reported outcome measures; Depression; HADS; Anxiety; Patient satisfaction
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/s12883-023-03090-0

Multiple sclerosis (MS) is a chronic disease affecting multiple functional aspects of patients' lives. Depression and anxiety are common amongst persons with MS (PwMS). There has been an interest in utilizing patient-reported outcome measures (PROMs) to capture and systematically assess patient's perceptions of their MS experience in addition to other clinical measures, but PROMs are not usually collected in routine clinical practice. Therefore, this study aims to systematically incorporate periodic electronically administered PROMs into the care of PwMS to evaluate its effects on depression and anxiety. A randomized controlled trial will be conducted with patients allocated 1:1 to either intervention or conservative treatment groups. Patients in the intervention group will complete PROMs at the start of the study and then every 6 months for 1 year, in addition to having their MS healthcare provider prompted to view their scores. The conservative treatment group will complete PROMs at the start of the study and again after 12 months, and their neurologist will not be able to view their scores. For both groups, pre-determined critical PROM scores will trigger an alert to the patient's MS provider. The difference in change in Hospital Anxiety and Depression Scale score between the intervention and conservative treatment groups at 12 months will be the primary outcome, along with difference in Consultation Satisfaction Questionnaire and CollaboRATE scores at 12 months, and proportion and type of healthcare provider intervention/alerts initiated by different PROMs as secondary outcomes. This study will determine the feasibility of utilizing PROMs on an interval basis and its effects on the psychological well-being of PwMS. Findings of this study will provide evidence on use of PROMs in future MS clinical practice. This trial is registered at the National Institutes of Health United States National Library of Medicine, ClinicalTrials.gov NCT04979546 . Registered on July 28, 2021.